TABLE 2

Effect of Data Exchange on Immunization Status and Overimmunization

Before Implementation (2009), %After Implementation (2010), %Absolute Difference (95% CI)Relative Risk (95% CI)
Percentage of Children Up to Date
 19–35 moa83.0 (1532/1846)93.0 (1673/1799)10.0 (7.9 to 12.1)1.12 (1.09 to 1.15)
 7–10 yb78.3 (1836/2344)82.5 (1769/2144)4.2 (1.8 to 6.5)1.05 (1.02 to 1.08)
 13–17 yc (includes 1 HPV dose)73.8 (1669/2262)79.5 (1734/2181)5.7 (3.2 to 8.3)1.08 (1.04 to 1.11)
 13–17 yd (includes 3 HPV doses)65.0 (1471/2262)71.3 (1556/2181)6.3 (3.5 to 9.1)1.10 (1.05 to 1.14)
 Totale75.0 (4839/6452)81.6 (4998/6124)6.6 (5.2 to 8.1)1.09 (1.07 to 1.11)
Percentage of Children With ≥1 Overimmunizationf
 19–35 mo10.4 (12/115)9.8 (18/184)−0.6 (−8.4 to 7.1)0.94 (0.47 to 1.87)
 7–10 y5.2 (9/172)2.1 (5/237)−3.1 (−7.4 to 1.2)0.40 (0.14 to 1.18)
 13–17 y16.4 (9/55)1.2 (1/85)−15.2 (−26.7 to −3.6)0.072 (0.009 to 0.55)
 Total8.8 (30/342)4.7 (24/506)−4.1 (−7.8 to −0.3)0.54 (0.32 to 0.91)
  • a 4:3:1:3:3:1:4 immunization series (4 doses of the DTaP vaccine, 3 doses of IPV, 21 dose of the MMR vaccine, ≥3 doses of the Hib vaccine, 3 doses of the hepatitis B vaccine, 1 dose of the varicella vaccine (chickenpox), and 4 doses of the pneumococcal conjugate vaccine.

  • b 4:3:1:3:3:1 series plus 1 booster dose each of DTaP, IPV, MMR, and varicella. Pneumococcal conjugate vaccine was not included because subjects would have been born before or soon after pneumococcal conjugate vaccine was licensed in 2000.

  • c 1:1:1 series: 1 dose of Tdap, 1 dose of meningococcal vaccine, and 1 dose of HPV. HPV vaccination was calculated only for girls because the routine recommendation for boys to receive HPV vaccine occurred in 2011, after the analytic periods. The second dose of the meningococcal vaccine, as a booster for older adolescents only, was also recommended in 2010 and therefore was not included.

  • d 1:1:3 series: as above but with 3 doses of HPV vaccine for girls.

  • e Includes 1:1:3 series for adolescents.

  • f Excess vaccinations: DTaP, IPV, MMR, Hib, hepatitis B, varicella, and pneumococcal vaccine for 19- to 35-mo-olds and 7- to 10-y-olds and Tdap, meningococcal vaccine, and HPV for 13- to 17-y-olds for children at high risk for overimmunization (with ≥1 immunization found only in the CIR).